Form 4: Imunon Inc. Insider Trading: Lindborg Acquires Stock

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 1,491 shares of common stock on May 22, 2026, as part of her compensation.

Summary

• Stacy Lindborg, President and CEO of Imunon, Inc., acquired 1,491 shares of common stock on May 22, 2026.
• The acquisition was made at a price of $2.20 per share.
• Following this transaction, Lindborg beneficially owns 3,642 shares of common stock.
• An additional 778 shares are held indirectly through a 401(k) plan.
• The shares were granted in lieu of a portion of her base salary.
• The filing also notes a 15% stock dividend paid on August 21, 2025, which adjusted previously reported share amounts.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents an insider acquisition as part of compensation, which can signal confidence, but it is not an open market purchase.

Positives

• Insider acquisition of stock by a key executive (President and CEO) can signal confidence in the company's future prospects.
• The acquisition is part of compensation, indicating a commitment to aligning executive interests with shareholder value.
• The transaction occurred at a specific price ($2.20), providing a data point for valuation.

Negatives

• The acquisition is a form of compensation rather than an open market purchase, which might be viewed differently by investors.
• The total number of shares acquired and held is relatively small in the context of a public company.

Risks

• The filing does not explicitly mention any risks associated with this transaction.
• General risks associated with Imunon, Inc.'s business operations and the biotechnology sector are not detailed in this specific filing.

Future Outlook

This filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Management Comments

• Stock granted in lieu of cash for portion of base salary.
• As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, especially by senior management, are often interpreted as a positive signal of management's belief in the company's value and future growth potential within the biotechnology sector.

Related Party Transactions

• The acquisition of stock by Stacy Lindborg, President and CEO, in lieu of cash for a portion of her base salary represents a transaction between the company and a related party (an executive officer).

Stakeholder Impact

• Shareholders: May view the insider acquisition positively as a sign of management confidence, though the compensation nature of the acquisition is a nuance.
• Employees: The compensation structure involving stock grants may influence employee morale and alignment with company performance.
• Management: Stacy Lindborg's beneficial ownership increases, aligning her financial interests more closely with shareholders.

Next Steps

• Continued reporting of changes in beneficial ownership as required by Section 16 of the Securities Exchange Act of 1934.

Key Dates

Keywords

Imunon Inc., IMNN, Form 4, Insider Trading, Stacy Lindborg, Stock Acquisition, Beneficial Ownership, Executive Compensation, SEC Filing